The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Publication
, Journal Article
Ramsey, LB; Johnson, SG; Caudle, KE; Haidar, CE; Voora, D; Wilke, RA; Maxwell, WD; McLeod, HL; Krauss, RM; Roden, DM; Feng, Q; Gong, L ...
Published in: Clin Pharmacol Ther
October 2014
Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
October 2014
Volume
96
Issue
4
Start / End Page
423 / 428
Location
United States
Related Subject Headings
- Simvastatin
- Polymorphism, Genetic
- Pharmacology & Pharmacy
- Pharmacogenetics
- Organic Anion Transporters
- Muscular Diseases
- Liver-Specific Organic Anion Transporter 1
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- Genotype
Citation
APA
Chicago
ICMJE
MLA
NLM
Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., … Niemi, M. (2014). The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther, 96(4), 423–428. https://doi.org/10.1038/clpt.2014.125
Ramsey, L. B., S. G. Johnson, K. E. Caudle, C. E. Haidar, D. Voora, R. A. Wilke, W. D. Maxwell, et al. “The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.” Clin Pharmacol Ther 96, no. 4 (October 2014): 423–28. https://doi.org/10.1038/clpt.2014.125.
Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423–8.
Ramsey, L. B., et al. “The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.” Clin Pharmacol Ther, vol. 96, no. 4, Oct. 2014, pp. 423–28. Pubmed, doi:10.1038/clpt.2014.125.
Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423–428.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
October 2014
Volume
96
Issue
4
Start / End Page
423 / 428
Location
United States
Related Subject Headings
- Simvastatin
- Polymorphism, Genetic
- Pharmacology & Pharmacy
- Pharmacogenetics
- Organic Anion Transporters
- Muscular Diseases
- Liver-Specific Organic Anion Transporter 1
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- Genotype